NPXe Files Chapter 11 to implement Asset Sale
Inspiration Healthcare Group plc
("Inspiration Healthcare", the "Company" or the "Group")
NPXe Files Voluntary Chapter 11 to implement Asset Sale
Inspiration Healthcare Group plc (AIM:IHC), the global medical technology company has been made aware that NPXe Limited ("NPXe") a company in which Inspiration Healthcare holds circa 8.6% of the issued share capital, that NPXe has filed a voluntary petition to reorganize under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. NPXe has also filed a motion seeking authorization to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code.
NPXe is a Phase III pharmaceutical and drug delivery device company developing XENEX™ (xenon gas for inhalation) for neuro- and cardio-protection and improvement in survival for post-cardiac arrest syndrome.
For further information on the process and timetable, please contact NeuroproteXeon directly (www.npxe.com).
Inspiration Healthcare's holding in NPXe is currently valued at £111,000 on its balance sheet. Should the sale of NXPe proceed the Company will issue a further statement to update shareholders on details of any proceeds receivable from the sale.
The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
Inspiration Healthcare Group plc
Neil Campbell, Chief Executive Officer
Mike Briant, Chief Financial Officer
Tel: 01455 840555
Nominated Adviser & Broker
Cenkos Securities plc
Mark Connelly / Stephen Keys
Tel: 0207 397 8900
Tel: 07771 713608
About Inspiration Healthcare
Inspiration Healthcare (AIM: IHC) is a global provider of medical technology for use in critical care & operating theatres. The Company provides high quality innovative products to patients around the world which help to improve patient outcomes and it actively invests in innovative product opportunities and disruptive technologies.
Through investment in research and development the Company has 6 key own brand products that can be used within the first 6 hours of life to help premature and sick babies; helping with assessment, resuscitation, stabilisation as well as preventing brain damage. Additionally the Company has its own range of products for maintaining normothermia pre- during and post-surgery.
With product availability extending to over 50 countries through a distribution network, Inspiration Healthcare's success has been built on continuous innovation, excellent customer service and an inherent commitment to improving patient outcomes, working in close collaboration with key opinion leaders across the globe.
In the UK and Ireland the Company has a direct sales team selling Inspiration Branded and complementary products from third parties, with an additional range of home healthcare products. This is supported by Technical Support for planned preventative maintenance and emergency assistance.
Further information on Inspiration Healthcare can be seen at www.inspiration-healthcare.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.